From Chronic Kidney Disease to Cancer Care: The Expanding Role of Erythropoietin Drugs
The increasing prevalence of anemia associated with chronic kidney disease, cancer, and other chronic conditions is driving demand for erythropoietin drugs in the United States. However, the market also faces several challenges. High treatment costs, pricing pressure from biosimilars, safety concerns related to long-term use, and stringent regulatory requirements can affect market...
0 Комментарии 0 Поделились 293 Просмотры 0 предпросмотр